Finance

Lists
8QQ:FRA
AbCellera Biologics Inc
€9.87
+4.22%
(+0.40) 1D
Sep 4, 10:00:00 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 8QQ...
Open
€9.88
High
€9.88
Low
€9.87
Mkt. cap
3.70B
Avg. vol.
1.43K
Volume
25.00
52-wk high
€10.78
52-wk low
€2.49
No. of employees
562
Open
€9.88
High
€9.88
Low
€9.87
Mkt. cap
3.70B
Avg. vol.
1.43K
Volume
25.00
52-wk high
€10.78
52-wk low
€2.49
No. of employees
562
Profile
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
About AbCellera Biologics Inc
CEOCarl Hansen
Employees562
Founded2012
HeadquartersVancouver, British Columbia, Canada
SectorHealth care
Websiteabcellera.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
8.96M
44.85M
8.32M
4.05M
Cost of goods sold
55.03M
50.09M
46.66M
45.99M
Cost of revenue
55.03M
50.09M
46.66M
45.99M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
24.96M
17.22M
12.33M
13.85M
Operating expense
30.20M
23.34M
19.17M
20.84M
Total operating expenses
85.23M
73.44M
65.83M
66.83M
Operating income
-76.28M
-28.58M
-57.52M
-62.78M
Other non operating income
745.00K
2.16M
4.34M
3.85M
EBT including unusual items
-68.77M
-19.50M
-49.54M
-58.96M
EBT excluding unusual items
-68.77M
-20.50M
-49.54M
-58.96M
Income tax expense
-11.65M
-10.55M
-6.37M
-3.54M
Effective tax rate
16.94%
54.13%
12.86%
6.00%
Other operating expenses
-
-
-
-
Net income
-57.12M
-8.94M
-43.16M
-55.43M
Net profit margin
-637.84%
-19.94%
-519.12%
-1,368.57%
Earnings per share
-0.19
-0.03
-0.14
-0.18
Interest and investment income
6.76M
5.92M
3.64M
-
Interest expense
-
-
-
-42.00K
Net interest expenses
6.76M
5.92M
3.64M
-42.00K
Depreciation and amortization charges
5.25M
6.12M
6.84M
6.99M
EBITDA
-71.03M
-22.46M
-50.68M
-55.79M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps